FI3849970T3 - Kiteinen (r)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli)piperatsiini-1-karboksylaatti, sen koostumuksia ja käyttömenetelmiä - Google Patents

Kiteinen (r)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli)piperatsiini-1-karboksylaatti, sen koostumuksia ja käyttömenetelmiä Download PDF

Info

Publication number
FI3849970T3
FI3849970T3 FIEP19778721.1T FI19778721T FI3849970T3 FI 3849970 T3 FI3849970 T3 FI 3849970T3 FI 19778721 T FI19778721 T FI 19778721T FI 3849970 T3 FI3849970 T3 FI 3849970T3
Authority
FI
Finland
Prior art keywords
crystal form
degrees
powder
ray diffraction
diffraction pattern
Prior art date
Application number
FIEP19778721.1T
Other languages
English (en)
Finnish (fi)
Inventor
Lianfeng Huang
Nancy Tsou
Nicole White
Jun Xu
Qun Zhang
Original Assignee
Celgene Corp
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Lundbeck La Jolla Research Center Inc filed Critical Celgene Corp
Application granted granted Critical
Publication of FI3849970T3 publication Critical patent/FI3849970T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP19778721.1T 2018-09-13 2019-09-12 Kiteinen (r)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli)piperatsiini-1-karboksylaatti, sen koostumuksia ja käyttömenetelmiä FI3849970T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3849970T3 true FI3849970T3 (fi) 2024-09-20

Family

ID=68069873

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP19778721.1T FI3849970T3 (fi) 2018-09-13 2019-09-12 Kiteinen (r)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli)piperatsiini-1-karboksylaatti, sen koostumuksia ja käyttömenetelmiä
FIEP24185102.1T FI4434583T3 (fi) 2018-09-13 2019-09-12 Kiteinen(R)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli) piperatsiini-1-karboksylaatti, sen koostumukset ja käytöt

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP24185102.1T FI4434583T3 (fi) 2018-09-13 2019-09-12 Kiteinen(R)-5-karbamoyylipyridin-3-yyli-2-metyyli-4-(3-(trifluorimetoksi)bentsyyli) piperatsiini-1-karboksylaatti, sen koostumukset ja käytöt

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
KR20210057789A (ko) 2021-05-21
US11053199B2 (en) 2021-07-06
MA53607A (fr) 2021-12-22
EP4434583A2 (en) 2024-09-25
JP2022500441A (ja) 2022-01-04
HUE068147T2 (hu) 2024-12-28
KR102844245B1 (ko) 2025-08-11
ES2993173T3 (en) 2024-12-23
WO2020056105A9 (en) 2020-07-09
MX2021002923A (es) 2021-09-08
FI4434583T3 (fi) 2026-05-15
HRP20260757T1 (hr) 2026-08-14
EP4434583B1 (en) 2026-04-01
PL3849970T3 (pl) 2025-01-07
AU2019337623A1 (en) 2021-05-13
US20210363105A1 (en) 2021-11-25
RS68181B1 (sr) 2026-06-30
LT3849970T (lt) 2024-10-10
US20260062384A1 (en) 2026-03-05
US11680046B2 (en) 2023-06-20
PL4434583T3 (pl) 2026-07-20
DK4434583T5 (da) 2026-07-06
EP4434583A3 (en) 2024-11-20
SG11202102143RA (en) 2021-04-29
MY208901A (en) 2025-06-09
EP3849970A1 (en) 2021-07-21
CA3112200A1 (en) 2020-03-19
AU2019337623B2 (en) 2024-12-05
IL281276A (en) 2021-04-29
SMT202400369T1 (it) 2024-11-15
EP4768081A2 (en) 2026-07-01
EA202190511A1 (ru) 2021-07-05
EP3849970B1 (en) 2024-07-03
SMT202600252T1 (it) 2026-07-16
PT3849970T (pt) 2024-09-25
SI3849970T1 (sl) 2024-11-29
IL281276B2 (en) 2025-01-01
IL281276B1 (en) 2024-09-01
CN113227069B (zh) 2024-11-05
MY210363A (en) 2025-09-13
CL2021000596A1 (es) 2021-07-30
LT4434583T (lt) 2026-06-25
DK4434583T3 (da) 2026-06-15
PT4434583T (pt) 2026-06-11
US12410133B2 (en) 2025-09-09
US20200095201A1 (en) 2020-03-26
WO2020056105A1 (en) 2020-03-19
MA53607B1 (fr) 2025-05-30
RS65967B1 (sr) 2024-10-31
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
CN118530218A (zh) 2024-08-23
CO2021003295A2 (es) 2021-07-30
ES3072981T3 (en) 2026-07-07
US20230382861A1 (en) 2023-11-30
MA71839B1 (fr) 2026-05-26
CN113227069A (zh) 2021-08-06
BR112021004340A2 (pt) 2021-05-25
CN118561814A (zh) 2024-08-30
DK3849970T3 (da) 2024-09-30

Similar Documents

Publication Publication Date Title
JP2021530565A5 (cg-RX-API-DMAC7.html)
JP2009537498A5 (cg-RX-API-DMAC7.html)
JP4619945B2 (ja) 置換されたホモピペリジン、ピペリジンまたはピロリジン誘導体
DE2247330A1 (de) Herbicide verbindung und verfahren zur herstellung derselben
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2018531280A5 (cg-RX-API-DMAC7.html)
EA200601266A1 (ru) Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
CA2600203A1 (en) New salt and polymorphs of a dpp-iv inhibitor
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JP2018524342A5 (cg-RX-API-DMAC7.html)
KR20090005369A (ko) 중추 신경계 질환의 치료를 위한 (2s)-(4e)-n-메틸-5-(3-이소프로폭시피리딘)일]-4-펜텐-2-아민의 다형체 제형
JP2005520819A5 (cg-RX-API-DMAC7.html)
RU2019110048A (ru) Твердые формы валбеназина
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
JP2024530164A5 (cg-RX-API-DMAC7.html)
JP2018503649A5 (cg-RX-API-DMAC7.html)
WO2014164648A4 (en) Solid state forms of a quinazoline derivative and its use as a braf inhibitor
RU2013120549A (ru) Новые кристаллические формы натриевой соли(4-{4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты
RU2008137725A (ru) Новая соль
HRP20241294T1 (hr) Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoksi)benzil) piperazin-1-karboksilat, pripravci i postupci njegove upotrebe
WO2010045582A3 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
CA2553345A1 (en) Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
Kouznetsov et al. Transformation of schiff bases derived from alpha‐naphthaldehyde. Synthesis, spectral data and biological activity of new‐3‐aryl‐2‐(α‐naphtyl)‐4‐thiazolidinones and N‐aryl‐N‐[1‐(α‐naphthyl) but‐3‐enyl] amines
JPH09328477A (ja) 除草性イソオキサゾリン誘導体
Panda et al. Microwave Induced Synthesis of 1, 2, 4-triazole derivatives and Study of their Anthelmintic and Anti-microbial Activities